Duloxetine Does Not Relieve Painful Physical Symptoms in Depression: A Meta-AnalysisSpielmans G.I.
Department of Psychology, Metropolitan State University, Saint Paul, Minn., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background:Duloxetine inhibits both serotonin and norepinephrine reuptake and is marketed as a treatment for both the core emotional symptoms and painful physical complaints that often accompany depression. Some studies have found that duloxetine is efficacious in treating painful symptoms associated with depression but these findings have been inconsistent. Several narrative review articles have reached positive conclusions about the efficacy of duloxetine as an analgesic in depression but there has been no quantitative systematic review regarding the impact of duloxetine on pain among this population. A meta-analysis of data pertaining to duloxetine’s purported analgesic effects on depressed patients was thus undertaken. Methods:Studies were selected through searching Medline and Cochrane Trial databases as well as examining Lilly’s public clinical trial database. A random effects model was used. Results: Across five trials, the results indicate a very small (d = 0.115) and statistically nonsignificant (p = 0.057) analgesic effect for duloxetine. Additionally, some of the relevant data on duloxetine’s effects have not been reported fully, making it likely that the obtained results reflect an overestimate of its true impact on painful physical symptoms in depression. Discussion:The current analysis is based on a small number of studies; further trials may yield significant results favoring duloxetine. Based upon the currently available evidence, the marketing of duloxetine as an antidepressant with analgesic properties for people with depression does not appear to be adequately supported.
© 2008 S. Karger AG, Basel
- Garcia-Cebrian A, Gandhi P, Demyttenaere K, Peveler R: The association of depression and painful physical symptoms – a review of the European literature. Eur Psychiatry 2006;21:379–388.
- Henningsen P, Lowe B: Depression, pain, and somatoform disorders. Curr Opin Psychiatry 2006;19:19–24.
- Trivedi MH: Major depressive disorder: remission of associated symptoms. J Clin Psychiatry 2006;67(suppl 6):27–32.
- Ohayon MM, Schatzberg AF: Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003;60:39–47.
Von Korff M, Simon G: The relationship between pain and depression. Br J Psychiatry 1996;30(suppl):101–108.
- Bair MJ, Robinson RL, Eckert GJ, Stang PE, Croghan TW, Kroenke K: Impact of pain on depression treatment response in primary care. Psychosom Med 2004;66:17–22.
- Cowen PJ, Oglivie AD, Gama J: Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression. Curr Med Res Opin 2005;21:345–355.
- Lynch ME: Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001;26:30–36.
- Stewart DE: Physical symptoms of depression: unmet needs in special populations. J Clin Psychiatry 2003;64(suppl 7):12–16.
- Mallinckrodt CH, Goldstein DJ, Detke MJ, Lu Y, Watkin JG, Tran PV: Duloxetine: a new treatment for the emotional and physical symptoms of depression. Prim Care Companion J Clin Psychiatry 2003;5:19–28.
Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, Tran PV: Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;26:106–132.
- Schatzberg AF: Efficacy and tolerability of duloxetine, a novel dual reptake inhibitor in the treatment of major depressive disorder. J Clin Psychiatry 2003;64(suppl 13):30–37.
- Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA: Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004;45:17–28.
Moore D, Zimm A: Eli Lilly net rises as Cymbalta sales almost double (update 5). http://www.bloomberg.com/apps/news?pid =newsarchive&sid=aN6ts3UJxl2Y
- Clark P, Lavielle P, Martinez H: Learning from pain scales: patient perspective. J Rheumatol 2003;30:1584–1588.
- Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS: Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004;20:309–318.
- Muñoz RA, McBride ME, Brnabic AJM, Lopez CJ, Hetem LAB, Secin R, Dueñas HJ: Major depressive disorder in Latin America: the relationship between depression severity, painful somatic symptoms, and quality of life. J Affect Disord 2005;86:93–98.
Hedges LV, Olkin I: Statistical Methods for Meta-Analysis. San Diego, Academic Press, 1985.
Comprehensive Meta-Analysis (version 2.2.03). Englewood, Biostat, 2006.
Gleser LJ, Olkin I: Stochastically dependent effect sizes; in Cooper H, Hedges LV (eds): The Handbook of Research Synthesis. New York, Russell Sage, 1994, pp 339–356.
Wampold BE, Mondin G, Moody M, Stich F, Ahn H: A meta-analysis of outcome studies comparing bona fide psychotherapies: empirically, ‘All must have prizes.’ Psych Bull 1997;122:203–215.
- Hardy RJ, Thompson SG: Detecting and describing heterogeneity in meta- analysis. Stat Med 1998;17:841–856.
- Hedges LV, Pigott TD: The power of statistical tests in meta-analysis. Psychol Methods 2001;6:203–217.
- Higgins JPT, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analysis. BMJ 2003;327:557–560.
Hedges LV: Statistical considerations; in Cooper H, Hedges LV (eds): The Handbook of Research Synthesis. New York, Russell Sage, 1994, pp 29–38.
Study 4091a. Duloxetine versus Placebo and Paroxetine in the Acute Treatment of Major Depression. http://lillytrials.com/results_files/cymbalta/cymbalta_summary_4091a.pdf
Study 4091b. Duloxetine versus Placebo and Paroxetine in the Acute Treatment of Major Depression. http://lillytrials.com/results_files/cymbalta/cymbalta_summary_4091b.pdf
Study 4689a. Duloxetine Once-Daily Dosing versus Placebo in the Acute Treatment of Major Depression. http://lillytrials.com/results_files/cymbalta/cymbalta_summary_4689a.pdf
Study 4689b. Duloxetine Once-Daily Dosing versus Placebo in the Acute Treatment of Major Depression. http://lillytrials.com/results_files/cymbalta/cymbalta_summary_4689b.pdf
Study 6553. Duloxetine Once-Daily Dosing versus Placebo in Patients with Major Depression and Pain. http://lillytrials.com/results_files/cymbalta/cymbalta_summary_6353.pdf
Cohen J: Statistical Power Analysis for the Behavioral Sciences, ed 2. Hillsdale, Erlbaum, 1988.
- Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF: Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39:43–53.
- Detke MH, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I: Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457–470.
- Perahia DGS, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ: Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 2006;21:367–378.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.